JP2024059632A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024059632A5 JP2024059632A5 JP2024012755A JP2024012755A JP2024059632A5 JP 2024059632 A5 JP2024059632 A5 JP 2024059632A5 JP 2024012755 A JP2024012755 A JP 2024012755A JP 2024012755 A JP2024012755 A JP 2024012755A JP 2024059632 A5 JP2024059632 A5 JP 2024059632A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- deficiency
- use according
- cancer
- cancer cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 22
- 201000011510 cancer Diseases 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 230000007812 deficiency Effects 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 102100029094 DNA repair endonuclease XPF Human genes 0.000 claims 4
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims 4
- 101000632626 Homo sapiens Shieldin complex subunit 2 Proteins 0.000 claims 4
- 101000632624 Homo sapiens Shieldin complex subunit 3 Proteins 0.000 claims 4
- 101000702606 Homo sapiens Structure-specific endonuclease subunit SLX4 Proteins 0.000 claims 4
- 102100024403 Nibrin Human genes 0.000 claims 4
- 239000012661 PARP inhibitor Substances 0.000 claims 4
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims 4
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims 4
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 claims 4
- 102100028378 Shieldin complex subunit 2 Human genes 0.000 claims 4
- 102100028385 Shieldin complex subunit 3 Human genes 0.000 claims 4
- 102100031003 Structure-specific endonuclease subunit SLX4 Human genes 0.000 claims 4
- 230000034431 double-strand break repair via homologous recombination Effects 0.000 claims 4
- 230000037361 pathway Effects 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 101700002522 BARD1 Proteins 0.000 claims 2
- 108700020463 BRCA1 Proteins 0.000 claims 2
- 102000036365 BRCA1 Human genes 0.000 claims 2
- 101150072950 BRCA1 gene Proteins 0.000 claims 2
- 102100028048 BRCA1-associated RING domain protein 1 Human genes 0.000 claims 2
- 108700020462 BRCA2 Proteins 0.000 claims 2
- 102000052609 BRCA2 Human genes 0.000 claims 2
- 102100035631 Bloom syndrome protein Human genes 0.000 claims 2
- 108091009167 Bloom syndrome protein Proteins 0.000 claims 2
- 101150008921 Brca2 gene Proteins 0.000 claims 2
- 102100040484 Claspin Human genes 0.000 claims 2
- 101710117926 Claspin Proteins 0.000 claims 2
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims 2
- 102100029995 DNA ligase 1 Human genes 0.000 claims 2
- 102100039116 DNA repair protein RAD50 Human genes 0.000 claims 2
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims 2
- 102100027700 DNA-directed RNA polymerase I subunit RPA2 Human genes 0.000 claims 2
- 102100033996 Double-strand break repair protein MRE11 Human genes 0.000 claims 2
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 claims 2
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 claims 2
- 102000018825 Fanconi Anemia Complementation Group C protein Human genes 0.000 claims 2
- 108010027673 Fanconi Anemia Complementation Group C protein Proteins 0.000 claims 2
- 102000013601 Fanconi Anemia Complementation Group D2 protein Human genes 0.000 claims 2
- 108010026653 Fanconi Anemia Complementation Group D2 protein Proteins 0.000 claims 2
- 102000010634 Fanconi Anemia Complementation Group E protein Human genes 0.000 claims 2
- 108010077898 Fanconi Anemia Complementation Group E protein Proteins 0.000 claims 2
- 102000012216 Fanconi Anemia Complementation Group F protein Human genes 0.000 claims 2
- 108010022012 Fanconi Anemia Complementation Group F protein Proteins 0.000 claims 2
- 102000007122 Fanconi Anemia Complementation Group G protein Human genes 0.000 claims 2
- 108010033305 Fanconi Anemia Complementation Group G protein Proteins 0.000 claims 2
- 102000052930 Fanconi Anemia Complementation Group L protein Human genes 0.000 claims 2
- 108700026162 Fanconi Anemia Complementation Group L protein Proteins 0.000 claims 2
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims 2
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims 2
- 102100027285 Fanconi anemia group B protein Human genes 0.000 claims 2
- 102100034554 Fanconi anemia group I protein Human genes 0.000 claims 2
- 102100034553 Fanconi anemia group J protein Human genes 0.000 claims 2
- 102100034552 Fanconi anemia group M protein Human genes 0.000 claims 2
- 101000785776 Homo sapiens Artemin Proteins 0.000 claims 2
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 claims 2
- 101000863770 Homo sapiens DNA ligase 1 Proteins 0.000 claims 2
- 101000743929 Homo sapiens DNA repair protein RAD50 Proteins 0.000 claims 2
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims 2
- 101000729474 Homo sapiens DNA-directed RNA polymerase I subunit RPA1 Proteins 0.000 claims 2
- 101000650600 Homo sapiens DNA-directed RNA polymerase I subunit RPA2 Proteins 0.000 claims 2
- 101000591400 Homo sapiens Double-strand break repair protein MRE11 Proteins 0.000 claims 2
- 101100119754 Homo sapiens FANCL gene Proteins 0.000 claims 2
- 101000914679 Homo sapiens Fanconi anemia group B protein Proteins 0.000 claims 2
- 101000848174 Homo sapiens Fanconi anemia group I protein Proteins 0.000 claims 2
- 101000848171 Homo sapiens Fanconi anemia group J protein Proteins 0.000 claims 2
- 101000848187 Homo sapiens Fanconi anemia group M protein Proteins 0.000 claims 2
- 101000619640 Homo sapiens Leucine-rich repeats and immunoglobulin-like domains protein 1 Proteins 0.000 claims 2
- 101001128138 Homo sapiens NACHT, LRR and PYD domains-containing protein 2 Proteins 0.000 claims 2
- 101000702559 Homo sapiens Probable global transcription activator SNF2L2 Proteins 0.000 claims 2
- 101001092206 Homo sapiens Replication protein A 32 kDa subunit Proteins 0.000 claims 2
- 101001092125 Homo sapiens Replication protein A 70 kDa DNA-binding subunit Proteins 0.000 claims 2
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims 2
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 2
- 101000654630 Homo sapiens Shieldin complex subunit 1 Proteins 0.000 claims 2
- 101000702545 Homo sapiens Transcription activator BRG1 Proteins 0.000 claims 2
- 101000804798 Homo sapiens Werner syndrome ATP-dependent helicase Proteins 0.000 claims 2
- 102100031021 Probable global transcription activator SNF2L2 Human genes 0.000 claims 2
- 102100035729 Replication protein A 70 kDa DNA-binding subunit Human genes 0.000 claims 2
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims 2
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 2
- 102100032737 Shieldin complex subunit 1 Human genes 0.000 claims 2
- 102100031027 Transcription activator BRG1 Human genes 0.000 claims 2
- 102100035336 Werner syndrome ATP-dependent helicase Human genes 0.000 claims 2
- 230000007547 defect Effects 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000004083 survival effect Effects 0.000 claims 2
- 108010073629 xeroderma pigmentosum group F protein Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024012755A JP2024059632A (ja) | 2019-08-09 | 2024-01-31 | 新規の治療的使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2019/052243 WO2021028644A1 (en) | 2019-08-09 | 2019-08-09 | Novel therapeutic use |
| JP2022507857A JP2023501038A (ja) | 2019-08-09 | 2019-08-09 | 新規の治療的使用 |
| JP2024012755A JP2024059632A (ja) | 2019-08-09 | 2024-01-31 | 新規の治療的使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507857A Division JP2023501038A (ja) | 2019-08-09 | 2019-08-09 | 新規の治療的使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024059632A JP2024059632A (ja) | 2024-05-01 |
| JP2024059632A5 true JP2024059632A5 (https=) | 2024-07-03 |
Family
ID=74570294
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507857A Ceased JP2023501038A (ja) | 2019-08-09 | 2019-08-09 | 新規の治療的使用 |
| JP2024012755A Pending JP2024059632A (ja) | 2019-08-09 | 2024-01-31 | 新規の治療的使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022507857A Ceased JP2023501038A (ja) | 2019-08-09 | 2019-08-09 | 新規の治療的使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220387544A1 (https=) |
| EP (1) | EP4010002A1 (https=) |
| JP (2) | JP2023501038A (https=) |
| CN (1) | CN114728036A (https=) |
| CA (1) | CA3149112A1 (https=) |
| WO (1) | WO2021028644A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12358886B2 (en) * | 2019-08-09 | 2025-07-15 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
| EP4455129A4 (en) * | 2021-12-30 | 2025-05-07 | Shanghai Apeiron Therapeutics Company Limited | Dna polymerase theta inhibitor and use thereof |
| TW202332442A (zh) | 2022-01-31 | 2023-08-16 | 瑞士商瑞森製藥公司 | ＰＯＬθ抑制劑 |
| WO2024197653A1 (en) * | 2023-03-29 | 2024-10-03 | Suzhou Eoc Medical Research Co., Ltd. | Heterocyclic compounds and uses thereof |
| WO2025011603A1 (zh) * | 2023-07-12 | 2025-01-16 | 南京再明医药有限公司 | 一种化合物用于预防或治疗53BP1/Shieldin复合物缺陷的癌症的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013133876A1 (en) * | 2011-12-07 | 2013-09-12 | The Regents Of The University Of California | Biomarkers for prediction of response to parp inhibition in breast cancer |
| WO2017070198A1 (en) * | 2015-10-19 | 2017-04-27 | Dana-Farber Cancer Institute, Inc. | Polymerase q as a target in hr-deficient cancers |
| US12358886B2 (en) * | 2019-08-09 | 2025-07-15 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
-
2019
- 2019-08-09 CA CA3149112A patent/CA3149112A1/en active Pending
- 2019-08-09 JP JP2022507857A patent/JP2023501038A/ja not_active Ceased
- 2019-08-09 CN CN201980101223.8A patent/CN114728036A/zh active Pending
- 2019-08-09 WO PCT/GB2019/052243 patent/WO2021028644A1/en not_active Ceased
- 2019-08-09 US US17/597,940 patent/US20220387544A1/en not_active Abandoned
- 2019-08-09 EP EP19755666.5A patent/EP4010002A1/en not_active Withdrawn
-
2024
- 2024-01-31 JP JP2024012755A patent/JP2024059632A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024059632A5 (https=) | ||
| CL2021000862A1 (es) | Un inhibidor de la quinasa atr para utilizar en un método para tratar una enfermedad hiperproliferativa (divisional de la solicitud 201902431) | |
| Murai et al. | BRCAness, homologous recombination deficiencies, and synthetic lethality | |
| JP2006528618A5 (https=) | ||
| De Lorenzo et al. | The elephant and the blind men: making sense of PARP inhibitors in homologous recombination deficient tumor cells | |
| Martin et al. | DNA repair deficiency as a therapeutic target in cancer | |
| Rimar et al. | The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies | |
| Owonikoko et al. | Phase 2 study of talazoparib in patients with homologous recombination repair–deficient squamous cell lung cancer: Lung-MAP substudy S1400G | |
| Dulaney et al. | Poly (ADP-ribose) polymerase activity and inhibition in cancer | |
| Bouwman et al. | The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance | |
| Ljungman | Targeting the DNA damage response in cancer | |
| JP5525447B2 (ja) | Ｐａｒｐ阻害剤としてのキノリノン誘導体 | |
| M Rosen et al. | Targeting the BRCA1/2 tumor suppressors | |
| Ratner et al. | Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer | |
| JP2010506939A5 (https=) | ||
| JP2007516241A5 (https=) | ||
| JP2017516784A5 (https=) | ||
| JP2006528618A (ja) | 癌を治療するための医薬の製造におけるＰＡＲＰ活性阻害性ＲＮＡｉの使用 | |
| FI3386546T3 (fi) | Yhdistelmä metastaattisen syövän tehokkaaseen hoitoon potilailla | |
| Xia et al. | Genetic polymorphisms of DNA repair genes and DNA repair capacity related to aflatoxin b1 (AFB1)-induced DNA damages | |
| JP2019501962A5 (https=) | ||
| Sakogawa et al. | Involvement of homologous recombination in the synergism between cisplatin and poly (ADP‐ribose) polymerase inhibition | |
| Pichierri et al. | Fanconi anemia proteins and the s phase checkpoint | |
| Patterson-Fortin et al. | Targeting Polymerase Theta (POL θ) for Cancer Therapy | |
| Ampolini et al. | The development of ATM inhibitors in cancer therapy |